{"protocolSection": {"identificationModule": {"nctId": "NCT02049814", "orgStudyIdInfo": {"id": "BASCN1201"}, "secondaryIdInfos": [{"id": "U1111-1147-3393", "type": "OTHER", "domain": "World Health Organization"}, {"id": "VOG-P4-001", "type": "OTHER", "domain": "Takeda ID"}], "organization": {"fullName": "Takeda", "class": "INDUSTRY"}, "briefTitle": "Efficacy and Safety of Voglibose Compared With Acarbose in Participants With Type 2 Diabetes", "officialTitle": "A Randomized, Open-label, Non-inferiority Study to Compare the Efficacy and Safety of Voglibose and Acarbose in Patients With Type 2 Diabetes Mellitus With Poor Control of Metformin"}, "statusModule": {"statusVerifiedDate": "2019-02", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2014-05-09", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2016-06-01", "type": "ACTUAL"}, "completionDateStruct": {"date": "2016-06-28", "type": "ACTUAL"}, "studyFirstSubmitDate": "2014-01-28", "studyFirstSubmitQcDate": "2014-01-28", "studyFirstPostDateStruct": {"date": "2014-01-30", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2018-08-13", "resultsFirstSubmitQcDate": "2018-08-13", "resultsFirstPostDateStruct": {"date": "2019-02-04", "type": "ACTUAL"}, "dispFirstSubmitDate": "2017-02-02", "dispFirstSubmitQcDate": "2017-02-02", "dispFirstPostDateStruct": {"date": "2017-02-03", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2019-02-15", "lastUpdatePostDateStruct": {"date": "2019-03-13", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Takeda", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "The primary purpose of this study is to evaluate the efficacy of voglibose versus acarbose combined with metformin in participants with type 2 diabetes mellitus (T2DM) by evaluating levels of glycosylated hemoglobin.", "detailedDescription": "The drug being tested in this study is called voglibose. Voglibose is being tested to treat type 2 diabetes in people who have diabetes that is inadequately controlled on metformin alone. This study will look at glycemic control in people who take voglibose.\n\nThe study will enroll 494 patients. All participants will be enrolled in a 2-week screening phase and a metformin run-in phase. Eligible participants will be randomly assigned (by chance, like flipping a coin) to one of the two treatment groups:\n\n* Metformin and Voglibose 0.2 mg\n* Metformin and Acarbose 50 mg\n\nAll participants will be asked to take their current dose of metformin tablets and either voglibose or acarbose tablets three times a day throughout the study.\n\nThis multi-center trial will be conducted in China. The overall time to participate in this study is up to 20 weeks and participants will make 8 visits to the clinic."}, "conditionsModule": {"conditions": ["Type 2 Diabetes Mellitus"], "keywords": ["Drug therapy"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE4"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 494, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Metformin + Voglibose 0.2 mg", "type": "EXPERIMENTAL", "description": "Metformin tablets, at the maximum tolerated dose \u22651000 mg/day, orally, for 12 weeks, in addition to voglibose 0.2 mg, tablets, orally, three times daily, for Weeks 1 and 2, followed by voglibose 0.3 mg, tablets, orally, three times daily, Weeks 3 through 12.", "interventionNames": ["Drug: Metformin", "Drug: Voglibose"]}, {"label": "Metformin + Acarbose 50 mg", "type": "ACTIVE_COMPARATOR", "description": "Metformin tablets, at the maximum tolerated dose \u22651000 mg/day, orally, for 12 weeks, in addition to acarbose 50 mg, tablets, orally, three times daily, Weeks 1 and 2, then acarbose 100 mg, tablets, orally, three times daily, Weeks 3 through 12.", "interventionNames": ["Drug: Metformin", "Drug: Acarbose"]}], "interventions": [{"type": "DRUG", "name": "Metformin", "description": "Metformin tablets", "armGroupLabels": ["Metformin + Acarbose 50 mg", "Metformin + Voglibose 0.2 mg"], "otherNames": ["Glucophage"]}, {"type": "DRUG", "name": "Voglibose", "description": "Voglibose tablets", "armGroupLabels": ["Metformin + Voglibose 0.2 mg"], "otherNames": ["Basen"]}, {"type": "DRUG", "name": "Acarbose", "description": "Acarbose tablets", "armGroupLabels": ["Metformin + Acarbose 50 mg"], "otherNames": ["Glucobay, Precose, Prandase"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 12", "description": "The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 12 or final visit relative to baseline.", "timeFrame": "Baseline, Week 12"}], "secondaryOutcomes": [{"measure": "Change From Baseline in HbA1c at Week 6", "description": "The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 6 relative to baseline.", "timeFrame": "Baseline and Week 6"}, {"measure": "Change From Baseline in Fasting Blood Glucose Over Time", "description": "The change between the fasting blood glucose value collected at weeks 6 and 12 or final visit relative to baseline.", "timeFrame": "Baseline, Weeks 6 and 12"}, {"measure": "Change From Baseline in Postprandial Plasma Glucose (PPG) Over Time", "description": "The change between the value of glucose after 1 and 2 hours of meal, measured by the meal tolerance test collected at Weeks 6 and 12 or relative to baseline.", "timeFrame": "1 and 2 hours after meal at Baseline, Weeks 6 and 12"}, {"measure": "Change From Baseline in Fasting Insulin at Week 12", "description": "The change between the fasting insulin value collected at week 12 or final visit relative to baseline.", "timeFrame": "Baseline, Week 12"}, {"measure": "Change From Baseline in Postprandial Serum Insulin at Week 12", "description": "The change from Baseline in postprandial serum insulin, after 1 and 2 hours of meal collected at Week 12 relative to baseline.", "timeFrame": "1 and 2 hours after meal at Baseline and Week 12"}, {"measure": "Change From Baseline in Fasting Glucagon at Week 12", "description": "The change between the fasting glucagon value collected at week 12 or final visit relative to baseline.", "timeFrame": "Baseline, Week 12"}, {"measure": "Change From Baseline in Postprandial Serum Glucagon at Week 12", "description": "The change from Baseline in postprandial serum glucagon, after 1 and 2 hours of meal collected at Week 12 relative to baseline.", "timeFrame": "1 and 2 hours after meal at Baseline and Week 12"}, {"measure": "Change From Baseline in Calculated Homeostatic Model Assessment Insulin Resistance (HOMA IR) at Week 12", "description": "The change between the value of HOMA-IR collected at Week 12 and HOMA-IR collected at Baseline. HOMA IR measures insulin resistance based on fasting glucose and insulin measurements: HOMA IR = fasting plasma insulin (\u00b5IU/mL) \\* fasting plasma glucose (mmol/L) / 22.5. A higher number indicates a greater insulin resistance.", "timeFrame": "Baseline, Week 12"}, {"measure": "Change From Baseline in Insulin Homeostatic Model Assessment Beta Cell Function (HOMA \u03b2) at Week 12", "description": "The change between the value of HOMA-beta cell function collected at Week 12 and HOMA-beta cell function collected at Baseline. The homeostatic model assessment estimates steady state beta cell function as a percentage of a normal reference population (%B). HOMA %B = 20 \\* insulin (\u00b5IU/mL) / fasting plasma glucose (mmol/L) - 3.5.", "timeFrame": "Baseline, Week 12"}, {"measure": "Change From Baseline in Body Weight Over Time", "description": "The change between body weight at weeks 2, 6 and 12 or relative to baseline.", "timeFrame": "Baseline, Weeks 2, 6 and 12"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n1. Has a historical diagnosis of type 2 diabetes mellitus (T2DM) for at least 6 months prior to the screening visit (V1).\n2. Is male or female and aged from 18 to 75 years, inclusively.\n3. Has a body mass index (BMI) between 20 and 45 kg/m\\^2, inclusively.\n4. Is experiencing inadequate glycemic control with a glycosylated hemoglobin (HbA1c) concentration between 7.0% and 10.0%, inclusively.\n5. Has been treated with Metformin for at least 3 months and at a stable dose (\u22651000 mg/day) for at least 8 weeks prior to Screening, unless there is documentation that the participant's current dose is his or her maximum tolerated dose (MTD) and MTD is \u22641000 mg/day.\n6. Keeps constant body weight with fluctuation range no more than 10% over for at least 3 months before screening.\n7. Hemoglobin levels of the participant are \u226512 g/dL (\u2265120 g/L) in male and\u2265 10 g/dL (\u2265100 g/L) in female at screening visit.\n8. Male serum creatinine \\<1.5 mg/dL and female serum creatinine \\<1.4 mg/dL, or estimated glomerular filtration rate (eGFR) \\>60 ml/min/1.73m\\^2 based on calculation using the Modification of Diet in Renal Disease (MDRD) approximation at Screening.\n9. In the opinion of the investigator, the participant is capable of understanding and complying with protocol requirements.\n10. The participant or, when applicable, the participant's legally acceptable representative signs and dates a written informed consent form and any required privacy authorization prior to the initiation of any study procedures.\n\nExclusion Criteria:\n\n1. Type 1 diabetes mellitus.\n2. Has received insulin, voglibose, acarbose or other oral hypoglycemic drugs (except Metformin) for accumulative total of more than 7 days within the latest 3 months prior to Visit 1.\n3. Has a history of cardiovascular disease: acute myocardial infarction, class III or IV heart failure, or cerebrovascular accident (stroke) within the latest 3 months prior to Visit 1.\n4. The participant's liver function is damaged and has a significant clinical sign or symptom of hepatopathy, acute or chronic hepatitis, or the value of alanine aminotransferase (ALT) or aspartate aminotransferase (AST) is 3 times more than the upper limit of normal level at Visit 1.\n5. Has an active proliferative retinopathy or macular degeneration that need to have an urgent treatment in the opinion of investigators.\n6. Has a frequent attack of hypoglycemia or loses consciousness due to hypoglycemia in the opinion of investigators.\n7. Has one or more times ketoacidosis or hyperosmotic status/coma.\n8. Is receiving long-term (\\>14days) systemic glucocorticoid treatment (except the medicine: local, intraocular, inhalation or via the nose) or has received such treatment for 4 weeks at Visit 1.\n9. Has a hematopathy (e.g. hemolytic anemia, drepanocytosis) that may interfere with the HbA1c test.\n10. Has other liabilities (e.g. drug abuse, alcoholism or mental disorder) that may hinder the participant to follow and complete the study.\n11. Has participated in another clinical study within the past 90 days or has received any investigational compound within 30 days prior to randomization.\n12. Is unsuitable for this study in the opinion of investigators.\n13. Has a disease need to use other taboo or caution drugs that is not listed in this study.\n14. If female, is pregnant or lactating or intending to become pregnant before, during, or within 30 days after participating in this study.", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "75 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Medical Director, Clinical Science", "affiliation": "Takeda", "role": "STUDY_DIRECTOR"}], "locations": [{"city": "Hefei", "state": "Anhui", "country": "China", "geoPoint": {"lat": 31.86389, "lon": 117.28083}}, {"city": "Maanshan", "state": "Anhui", "country": "China"}, {"city": "Beijing", "state": "Beijing", "country": "China", "geoPoint": {"lat": 39.9075, "lon": 116.39723}}, {"city": "Guangzhou", "state": "Guangdong", "country": "China", "geoPoint": {"lat": 23.11667, "lon": 113.25}}, {"city": "Shenzhen", "state": "Guangdong", "country": "China", "geoPoint": {"lat": 22.54554, "lon": 114.0683}}, {"city": "Taishan", "state": "Guangdong", "country": "China", "geoPoint": {"lat": 22.25135, "lon": 112.7799}}, {"city": "Zhuzhou", "state": "Hunan", "country": "China", "geoPoint": {"lat": 27.83333, "lon": 113.15}}, {"city": "Nanjing", "state": "Jiangsu", "country": "China", "geoPoint": {"lat": 32.06167, "lon": 118.77778}}, {"city": "Xuzhou", "state": "Jiangsu", "country": "China", "geoPoint": {"lat": 34.18045, "lon": 117.15707}}, {"city": "Changchun", "state": "Jilin", "country": "China", "geoPoint": {"lat": 43.88, "lon": 125.32278}}, {"city": "Jilin", "state": "Jilin", "country": "China", "geoPoint": {"lat": 43.85083, "lon": 126.56028}}, {"city": "Shenyang", "state": "Liaoning", "country": "China", "geoPoint": {"lat": 41.79222, "lon": 123.43278}}, {"city": "Qingdao", "state": "Shandong", "country": "China", "geoPoint": {"lat": 36.06488, "lon": 120.38042}}, {"city": "Shanghai", "state": "Shanghai", "country": "China", "geoPoint": {"lat": 31.22222, "lon": 121.45806}}, {"city": "Yan An", "state": "Shanxi", "country": "China"}, {"city": "Yanan", "state": "Shanxi", "country": "China"}, {"city": "Tianjin", "state": "Tianjin", "country": "China", "geoPoint": {"lat": 39.14222, "lon": 117.17667}}, {"city": "Wenzhou", "state": "Zhejiang", "country": "China", "geoPoint": {"lat": 27.99942, "lon": 120.66682}}]}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "Participants with a diagnosis of type 2 diabetes mellitus (T2DM) were enrolled in 1:1 to receive voglibose combined with metformin or acarbose combined with metformin.", "recruitmentDetails": "Participants took part in the study at 22 investigative sites in China from 09 May 2014 to 28 June 2016.", "groups": [{"id": "FG000", "title": "Metformin + Voglibose 0.2 mg", "description": "Metformin tablets, at the maximum tolerated dose \u22651000 mg/day, orally, for 12 weeks, in addition to voglibose 0.2 mg, tablets, orally, three times daily, for Weeks 1 and 2, followed by voglibose 0.3 mg, tablets, orally, three times daily, Weeks 3 through 12."}, {"id": "FG001", "title": "Metformin + Acarbose 50 mg", "description": "Metformin tablets, at the maximum tolerated dose \u22651000 mg/day, orally, for 12 weeks, in addition to acarbose 50 mg, tablets, orally, three times daily, Weeks 1 and 2, then acarbose 100 mg, tablets, orally, three times daily, Weeks 3 through 12."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "248"}, {"groupId": "FG001", "numSubjects": "246"}]}, {"type": "Safety Set", "achievements": [{"groupId": "FG000", "numSubjects": "248"}, {"groupId": "FG001", "numSubjects": "245"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "219"}, {"groupId": "FG001", "numSubjects": "219"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "29"}, {"groupId": "FG001", "numSubjects": "27"}]}], "dropWithdraws": [{"type": "Reason not Specified", "reasons": [{"groupId": "FG000", "numSubjects": "4"}, {"groupId": "FG001", "numSubjects": "3"}]}, {"type": "Pregnancy", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "3"}]}, {"type": "Serious Protocol Violation", "reasons": [{"groupId": "FG000", "numSubjects": "5"}, {"groupId": "FG001", "numSubjects": "7"}]}, {"type": "Study Termination", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}]}, {"type": "Pretreatment event/Adverse Event (AE)", "reasons": [{"groupId": "FG000", "numSubjects": "8"}, {"groupId": "FG001", "numSubjects": "5"}]}, {"type": "Voluntary withdrawal", "reasons": [{"groupId": "FG000", "numSubjects": "9"}, {"groupId": "FG001", "numSubjects": "8"}]}]}]}, "baselineCharacteristicsModule": {"populationDescription": "Full Analysis Set (FAS) included participants who took investigational product after randomization and had at least one efficacy assessment after treatment.", "groups": [{"id": "BG000", "title": "Metformin + Voglibose 0.2 mg", "description": "Metformin tablets, at the maximum tolerated dose \u22651000 mg/day, orally, for 12 weeks, in addition to voglibose 0.2 mg, tablets, orally, three times daily, for Weeks 1 and 2, followed by voglibose 0.3 mg, tablets, orally, three times daily, Weeks 3 through 12."}, {"id": "BG001", "title": "Metformin + Acarbose 50 mg", "description": "Metformin tablets, at the maximum tolerated dose \u22651000 mg/day, orally, for 12 weeks, in addition to acarbose 50 mg, tablets, orally, three times daily, Weeks 1 and 2, then acarbose 100 mg, tablets, orally, three times daily, Weeks 3 through 12."}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "236"}, {"groupId": "BG001", "value": "233"}, {"groupId": "BG002", "value": "469"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "54.41", "spread": "9.239"}, {"groupId": "BG001", "value": "54.82", "spread": "9.386"}, {"groupId": "BG002", "value": "54.62", "spread": "9.305"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "114"}, {"groupId": "BG001", "value": "108"}, {"groupId": "BG002", "value": "222"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "122"}, {"groupId": "BG001", "value": "125"}, {"groupId": "BG002", "value": "247"}]}]}]}, {"title": "Race/Ethnicity, Customized", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "Ethnic Chinese", "categories": [{"measurements": [{"groupId": "BG000", "value": "236"}, {"groupId": "BG001", "value": "233"}, {"groupId": "BG002", "value": "469"}]}]}]}, {"title": "Region of Enrollment", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "China", "categories": [{"measurements": [{"groupId": "BG000", "value": "236"}, {"groupId": "BG001", "value": "233"}, {"groupId": "BG002", "value": "469"}]}]}]}, {"title": "Height", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "cm", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "164.8", "spread": "8.05"}, {"groupId": "BG001", "value": "165.2", "spread": "8.07"}, {"groupId": "BG002", "value": "165.0", "spread": "8.05"}]}]}]}, {"title": "Body Mass Index", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "kg/m^2", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "26.4", "spread": "3.27"}, {"groupId": "BG001", "value": "26.4", "spread": "3.63"}, {"groupId": "BG002", "value": "26.4", "spread": "3.45"}]}]}]}, {"title": "Baseline Systolic Blood Pressure (SBP)", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "mmHg", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "126.2", "spread": "12.22"}, {"groupId": "BG001", "value": "127.5", "spread": "12.69"}, {"groupId": "BG002", "value": "126.8", "spread": "12.46"}]}]}]}, {"title": "Baseline Diastolic Blood Pressure (DBP)", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "mmHg", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "76.5", "spread": "7.69"}, {"groupId": "BG001", "value": "77.7", "spread": "8.28"}, {"groupId": "BG002", "value": "77.1", "spread": "8.00"}]}]}]}, {"title": "Baseline Pulse", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "bpm", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "74.3", "spread": "7.73"}, {"groupId": "BG001", "value": "75.4", "spread": "8.47"}, {"groupId": "BG002", "value": "74.9", "spread": "8.12"}]}]}]}, {"title": "Baseline Temperature", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "\u00b0C", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "36.3", "spread": "0.27"}, {"groupId": "BG001", "value": "36.4", "spread": "0.25"}, {"groupId": "BG002", "value": "36.3", "spread": "0.26"}]}]}]}, {"title": "Baseline Weight", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "kg", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "71.6", "spread": "11.68"}, {"groupId": "BG001", "value": "72.0", "spread": "12.09"}, {"groupId": "BG002", "value": "71.8", "spread": "11.87"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 12", "description": "The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 12 or final visit relative to baseline.", "populationDescription": "Per Protocol Set (PPS) is a subset of FAS, including participants who completed treatment as was prescribed in protocol and had no important protocol deviation.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "percentage of glycated hemoglobin", "timeFrame": "Baseline, Week 12", "groups": [{"id": "OG000", "title": "Metformin + Voglibose 0.2 mg", "description": "Metformin tablets, at the maximum tolerated dose \u22651000 mg/day, orally, for 12 weeks, in addition to voglibose 0.2 mg, tablets, orally, three times daily, for Weeks 1 and 2, followed by voglibose 0.3 mg, tablets, orally, three times daily, Weeks 3 through 12."}, {"id": "OG001", "title": "Metformin + Acarbose 50 mg", "description": "Metformin tablets, at the maximum tolerated dose \u22651000 mg/day, orally, for 12 weeks, in addition to acarbose 50 mg, tablets, orally, three times daily, Weeks 1 and 2, then acarbose 100 mg, tablets, orally, three times daily, Weeks 3 through 12."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "156"}, {"groupId": "OG001", "value": "156"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.6982", "spread": "0.0742"}, {"groupId": "OG001", "value": "-0.9335", "spread": "0.0764"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "NON_INFERIORITY_OR_EQUIVALENCE", "nonInferiorityComment": "If the upper limit of 95% CI of Least Square Mean (LS mean) of HbA1C Changes was less than 0.4%, it was considered that the non-inferiority was established.", "pValue": "0.0001", "statisticalMethod": "Paired t-test"}]}, {"type": "SECONDARY", "title": "Change From Baseline in HbA1c at Week 6", "description": "The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 6 relative to baseline.", "populationDescription": "PPS is a subset of FAS, including participants who completed treatment as was prescribed in protocol and had no important protocol deviation.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "percentage of glycated hemoglobin", "timeFrame": "Baseline and Week 6", "groups": [{"id": "OG000", "title": "Metformin + Voglibose 0.2 mg", "description": "Metformin tablets, at the maximum tolerated dose \u22651000 mg/day, orally, for 12 weeks, in addition to voglibose 0.2 mg, tablets, orally, three times daily, for Weeks 1 and 2, followed by voglibose 0.3 mg, tablets, orally, three times daily, Weeks 3 through 12."}, {"id": "OG001", "title": "Metformin + Acarbose 50 mg", "description": "Metformin tablets, at the maximum tolerated dose \u22651000 mg/day, orally, for 12 weeks, in addition to acarbose 50 mg, tablets, orally, three times daily, Weeks 1 and 2, then acarbose 100 mg, tablets, orally, three times daily, Weeks 3 through 12."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "156"}, {"groupId": "OG001", "value": "156"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.4765", "spread": "0.0605"}, {"groupId": "OG001", "value": "-0.631", "spread": "0.0623"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Fasting Blood Glucose Over Time", "description": "The change between the fasting blood glucose value collected at weeks 6 and 12 or final visit relative to baseline.", "populationDescription": "PPS is a subset of FAS, including participants who completed treatment as was prescribed in protocol and had no important protocol deviation.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mmol/L", "timeFrame": "Baseline, Weeks 6 and 12", "groups": [{"id": "OG000", "title": "Metformin + Voglibose 0.2 mg", "description": "Metformin tablets, at the maximum tolerated dose \u22651000 mg/day, orally, for 12 weeks, in addition to voglibose 0.2 mg, tablets, orally, three times daily, for Weeks 1 and 2, followed by voglibose 0.3 mg, tablets, orally, three times daily, Weeks 3 through 12."}, {"id": "OG001", "title": "Metformin + Acarbose 50 mg", "description": "Metformin tablets, at the maximum tolerated dose \u22651000 mg/day, orally, for 12 weeks, in addition to acarbose 50 mg, tablets, orally, three times daily, Weeks 1 and 2, then acarbose 100 mg, tablets, orally, three times daily, Weeks 3 through 12."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "156"}, {"groupId": "OG001", "value": "156"}]}], "classes": [{"title": "Change at Week 6", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.4234", "spread": "0.1397"}, {"groupId": "OG001", "value": "-0.8851", "spread": "0.1438"}]}]}, {"title": "Change at Week 12", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.5041", "spread": "0.1398"}, {"groupId": "OG001", "value": "-0.8029", "spread": "0.1439"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Postprandial Plasma Glucose (PPG) Over Time", "description": "The change between the value of glucose after 1 and 2 hours of meal, measured by the meal tolerance test collected at Weeks 6 and 12 or relative to baseline.", "populationDescription": "PPS is a subset of FAS, including participants who completed treatment as was prescribed in protocol and had no important protocol deviation.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mmol/L", "timeFrame": "1 and 2 hours after meal at Baseline, Weeks 6 and 12", "groups": [{"id": "OG000", "title": "Metformin + Voglibose 0.2 mg", "description": "Metformin tablets, at the maximum tolerated dose \u22651000 mg/day, orally, for 12 weeks, in addition to voglibose 0.2 mg, tablets, orally, three times daily, for Weeks 1 and 2, followed by voglibose 0.3 mg, tablets, orally, three times daily, Weeks 3 through 12."}, {"id": "OG001", "title": "Metformin + Acarbose 50 mg", "description": "Metformin tablets, at the maximum tolerated dose \u22651000 mg/day, orally, for 12 weeks, in addition to acarbose 50 mg, tablets, orally, three times daily, Weeks 1 and 2, then acarbose 100 mg, tablets, orally, three times daily, Weeks 3 through 12."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "156"}, {"groupId": "OG001", "value": "156"}]}], "classes": [{"title": "Change at Week 6 (1 hour PPG)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-2.5149", "spread": "0.2308"}, {"groupId": "OG001", "value": "-3.8557", "spread": "0.2377"}]}]}, {"title": "Change at Week 12 (1 hour PPG)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-2.1187", "spread": "0.2376"}, {"groupId": "OG001", "value": "-2.1187", "spread": "0.2376"}]}]}, {"title": "Change at Week 6 (2 hour PPG)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-2.7461", "spread": "0.2553"}, {"groupId": "OG001", "value": "-4.0015", "spread": "0.2624"}]}]}, {"title": "Change at Week 12 (2 hour PPG)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-2.6099", "spread": "0.2632"}, {"groupId": "OG001", "value": "-3.2347", "spread": "0.2705"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Fasting Insulin at Week 12", "description": "The change between the fasting insulin value collected at week 12 or final visit relative to baseline.", "populationDescription": "PPS is a subset of FAS, including participants who completed treatment as was prescribed in protocol and had no important protocol deviation.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "\u03bcU/dL", "timeFrame": "Baseline, Week 12", "groups": [{"id": "OG000", "title": "Metformin + Voglibose 0.2 mg", "description": "Metformin tablets, at the maximum tolerated dose \u22651000 mg/day, orally, for 12 weeks, in addition to voglibose 0.2 mg, tablets, orally, three times daily, for Weeks 1 and 2, followed by voglibose 0.3 mg, tablets, orally, three times daily, Weeks 3 through 12."}, {"id": "OG001", "title": "Metformin + Acarbose 50 mg", "description": "Metformin tablets, at the maximum tolerated dose \u22651000 mg/day, orally, for 12 weeks, in addition to acarbose 50 mg, tablets, orally, three times daily, Weeks 1 and 2, then acarbose 100 mg, tablets, orally, three times daily, Weeks 3 through 12."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "156"}, {"groupId": "OG001", "value": "156"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.0319", "spread": "1.1481"}, {"groupId": "OG001", "value": "2.4169", "spread": "1.1959"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Postprandial Serum Insulin at Week 12", "description": "The change from Baseline in postprandial serum insulin, after 1 and 2 hours of meal collected at Week 12 relative to baseline.", "populationDescription": "PPS is a subset of FAS, including participants who completed treatment as was prescribed in protocol and had no important protocol deviation.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "\u03bcU/dL", "timeFrame": "1 and 2 hours after meal at Baseline and Week 12", "groups": [{"id": "OG000", "title": "Metformin + Voglibose 0.2 mg", "description": "Metformin tablets, at the maximum tolerated dose \u22651000 mg/day, orally, for 12 weeks, in addition to voglibose 0.2 mg, tablets, orally, three times daily, for Weeks 1 and 2, followed by voglibose 0.3 mg, tablets, orally, three times daily, Weeks 3 through 12."}, {"id": "OG001", "title": "Metformin + Acarbose 50 mg", "description": "Metformin tablets, at the maximum tolerated dose \u22651000 mg/day, orally, for 12 weeks, in addition to acarbose 50 mg, tablets, orally, three times daily, Weeks 1 and 2, then acarbose 100 mg, tablets, orally, three times daily, Weeks 3 through 12."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "156"}, {"groupId": "OG001", "value": "156"}]}], "classes": [{"title": "Change at Week 12 (1 hour)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.3435", "spread": "2.2504"}, {"groupId": "OG001", "value": "-1.44", "spread": "2.341"}]}]}, {"title": "Change at Week 12 (2 hours)", "categories": [{"measurements": [{"groupId": "OG000", "value": "3.2972", "spread": "3.0059"}, {"groupId": "OG001", "value": "-0.1526", "spread": "3.1145"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Fasting Glucagon at Week 12", "description": "The change between the fasting glucagon value collected at week 12 or final visit relative to baseline.", "populationDescription": "PPS is a subset of FAS, including participants who completed treatment as was prescribed in protocol and had no important protocol deviation.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "pg/mL", "timeFrame": "Baseline, Week 12", "groups": [{"id": "OG000", "title": "Metformin + Voglibose 0.2 mg", "description": "Metformin tablets, at the maximum tolerated dose \u22651000 mg/day, orally, for 12 weeks, in addition to voglibose 0.2 mg, tablets, orally, three times daily, for Weeks 1 and 2, followed by voglibose 0.3 mg, tablets, orally, three times daily, Weeks 3 through 12."}, {"id": "OG001", "title": "Metformin + Acarbose 50 mg", "description": "Metformin tablets, at the maximum tolerated dose \u22651000 mg/day, orally, for 12 weeks, in addition to acarbose 50 mg, tablets, orally, three times daily, Weeks 1 and 2, then acarbose 100 mg, tablets, orally, three times daily, Weeks 3 through 12."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "156"}, {"groupId": "OG001", "value": "156"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "5.7543", "spread": "6.0009"}, {"groupId": "OG001", "value": "11.4541", "spread": "6.2524"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Postprandial Serum Glucagon at Week 12", "description": "The change from Baseline in postprandial serum glucagon, after 1 and 2 hours of meal collected at Week 12 relative to baseline.", "populationDescription": "PPS is a subset of FAS, including participants who completed treatment as was prescribed in protocol and had no important protocol deviation.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "pg/mL", "timeFrame": "1 and 2 hours after meal at Baseline and Week 12", "groups": [{"id": "OG000", "title": "Metformin + Voglibose 0.2 mg", "description": "Metformin tablets, at the maximum tolerated dose \u22651000 mg/day, orally, for 12 weeks, in addition to voglibose 0.2 mg, tablets, orally, three times daily, for Weeks 1 and 2, followed by voglibose 0.3 mg, tablets, orally, three times daily, Weeks 3 through 12."}, {"id": "OG001", "title": "Metformin + Acarbose 50 mg", "description": "Metformin tablets, at the maximum tolerated dose \u22651000 mg/day, orally, for 12 weeks, in addition to acarbose 50 mg, tablets, orally, three times daily, Weeks 1 and 2, then acarbose 100 mg, tablets, orally, three times daily, Weeks 3 through 12."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "156"}, {"groupId": "OG001", "value": "156"}]}], "classes": [{"title": "Change at Week 12 (1 hour)", "categories": [{"measurements": [{"groupId": "OG000", "value": "20.4409", "spread": "5.683"}, {"groupId": "OG001", "value": "15.69", "spread": "5.9068"}]}]}, {"title": "Change at Week 12 (2 hours)", "categories": [{"measurements": [{"groupId": "OG000", "value": "34.8518", "spread": "6.41"}, {"groupId": "OG001", "value": "13.0188", "spread": "6.6143"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Calculated Homeostatic Model Assessment Insulin Resistance (HOMA IR) at Week 12", "description": "The change between the value of HOMA-IR collected at Week 12 and HOMA-IR collected at Baseline. HOMA IR measures insulin resistance based on fasting glucose and insulin measurements: HOMA IR = fasting plasma insulin (\u00b5IU/mL) \\* fasting plasma glucose (mmol/L) / 22.5. A higher number indicates a greater insulin resistance.", "populationDescription": "PPS is a subset of FAS, including participants who completed treatment as was prescribed in protocol and had no important protocol deviation.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Insulin resistance", "timeFrame": "Baseline, Week 12", "groups": [{"id": "OG000", "title": "Metformin + Voglibose 0.2 mg", "description": "Metformin tablets, at the maximum tolerated dose \u22651000 mg/day, orally, for 12 weeks, in addition to voglibose 0.2 mg, tablets, orally, three times daily, for Weeks 1 and 2, followed by voglibose 0.3 mg, tablets, orally, three times daily, Weeks 3 through 12."}, {"id": "OG001", "title": "Metformin + Acarbose 50 mg", "description": "Metformin tablets, at the maximum tolerated dose \u22651000 mg/day, orally, for 12 weeks, in addition to acarbose 50 mg, tablets, orally, three times daily, Weeks 1 and 2, then acarbose 100 mg, tablets, orally, three times daily, Weeks 3 through 12."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "156"}, {"groupId": "OG001", "value": "156"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.366", "spread": "0.5389"}, {"groupId": "OG001", "value": "0.4983", "spread": "0.5596"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Insulin Homeostatic Model Assessment Beta Cell Function (HOMA \u03b2) at Week 12", "description": "The change between the value of HOMA-beta cell function collected at Week 12 and HOMA-beta cell function collected at Baseline. The homeostatic model assessment estimates steady state beta cell function as a percentage of a normal reference population (%B). HOMA %B = 20 \\* insulin (\u00b5IU/mL) / fasting plasma glucose (mmol/L) - 3.5.", "populationDescription": "PPS is a subset of FAS, including participants who completed treatment as was prescribed in protocol and had no important protocol deviation.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Percentage beta cell function", "timeFrame": "Baseline, Week 12", "groups": [{"id": "OG000", "title": "Metformin + Voglibose 0.2 mg", "description": "Metformin tablets, at the maximum tolerated dose \u22651000 mg/day, orally, for 12 weeks, in addition to voglibose 0.2 mg, tablets, orally, three times daily, for Weeks 1 and 2, followed by voglibose 0.3 mg, tablets, orally, three times daily, Weeks 3 through 12."}, {"id": "OG001", "title": "Metformin + Acarbose 50 mg", "description": "Metformin tablets, at the maximum tolerated dose \u22651000 mg/day, orally, for 12 weeks, in addition to acarbose 50 mg, tablets, orally, three times daily, Weeks 1 and 2, then acarbose 100 mg, tablets, orally, three times daily, Weeks 3 through 12."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "156"}, {"groupId": "OG001", "value": "156"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "15.3149", "spread": "5.4717"}, {"groupId": "OG001", "value": "28.1739", "spread": "5.7253"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Body Weight Over Time", "description": "The change between body weight at weeks 2, 6 and 12 or relative to baseline.", "populationDescription": "PPS is a subset of FAS, including participants who completed treatment as was prescribed in protocol and had no important protocol deviation.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "kg", "timeFrame": "Baseline, Weeks 2, 6 and 12", "groups": [{"id": "OG000", "title": "Metformin + Voglibose 0.2 mg", "description": "Metformin tablets, at the maximum tolerated dose \u22651000 mg/day, orally, for 12 weeks, in addition to voglibose 0.2 mg, tablets, orally, three times daily, for Weeks 1 and 2, followed by voglibose 0.3 mg, tablets, orally, three times daily, Weeks 3 through 12."}, {"id": "OG001", "title": "Metformin + Acarbose 50 mg", "description": "Metformin tablets, at the maximum tolerated dose \u22651000 mg/day, orally, for 12 weeks, in addition to acarbose 50 mg, tablets, orally, three times daily, Weeks 1 and 2, then acarbose 100 mg, tablets, orally, three times daily, Weeks 3 through 12."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "156"}, {"groupId": "OG001", "value": "156"}]}], "classes": [{"title": "Change at Week 2", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.016", "spread": "0.1661"}, {"groupId": "OG001", "value": "-0.1731", "spread": "0.1725"}]}]}, {"title": "Change at Week 6", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.6315", "spread": "0.1412"}, {"groupId": "OG001", "value": "-0.7975", "spread": "0.1466"}]}]}, {"title": "Change at Week 12", "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.1563", "spread": "0.1878"}, {"groupId": "OG001", "value": "-1.4394", "spread": "0.1951"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "timeFrame": "Up to Week 14", "description": "At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment. Safety set included all randomized participants who received at least one dose of study treatment and had at least one subsequent safety assessment.", "eventGroups": [{"id": "EG000", "title": "Metformin + Voglibose 0.2 mg", "description": "Metformin tablets, at the maximum tolerated dose \u22651000 mg/day, orally, for 12 weeks, in addition to voglibose 0.2 mg, tablets, orally, three times daily, for Weeks 1 and 2, followed by voglibose 0.3 mg, tablets, orally, three times daily, Weeks 3 through 12.", "seriousNumAffected": 3, "seriousNumAtRisk": 248, "otherNumAffected": 38, "otherNumAtRisk": 248}, {"id": "EG001", "title": "Metformin + Acarbose 50 mg", "description": "Metformin tablets, at the maximum tolerated dose \u22651000 mg/day, orally, for 12 weeks, in addition to acarbose 50 mg, tablets, orally, three times daily, Weeks 1 and 2, then acarbose 100 mg, tablets, orally, three times daily, Weeks 3 through 12.", "seriousNumAffected": 5, "seriousNumAtRisk": 245, "otherNumAffected": 41, "otherNumAtRisk": 245}], "seriousEvents": [{"term": "Sudden hearing loss", "organSystem": "Ear and labyrinth disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 248}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 245}]}, {"term": "ALT increased", "organSystem": "Investigations", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 248}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 245}]}, {"term": "Abnormal liver function test", "organSystem": "Investigations", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 248}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 245}]}, {"term": "Cerebral ischemia", "organSystem": "Nervous system disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 248}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 245}]}, {"term": "Cerebral hemangioma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 248}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 245}]}, {"term": "Hepatic tumor", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 248}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 245}]}, {"term": "Local swelling", "organSystem": "General disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 248}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 245}]}, {"term": "Acute coronary syndrome", "organSystem": "Cardiac disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 248}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 245}]}], "otherEvents": [{"term": "Urinary tract infection", "organSystem": "Infections and infestations", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 15, "numAtRisk": 248}, {"groupId": "EG001", "numAffected": 9, "numAtRisk": 245}]}, {"term": "Flatulence", "organSystem": "Gastrointestinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 23, "numAtRisk": 248}, {"groupId": "EG001", "numAffected": 41, "numAtRisk": 245}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property."}, "pointOfContact": {"title": "Medical Director", "organization": "Takeda", "email": "trialdisclosures@takeda.com", "phone": "+1-877-825-3327"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000003920", "term": "Diabetes Mellitus"}, {"id": "D000003924", "term": "Diabetes Mellitus, Type 2"}], "ancestors": [{"id": "D000044882", "term": "Glucose Metabolism Disorders"}, {"id": "D000008659", "term": "Metabolic Diseases"}, {"id": "D000004700", "term": "Endocrine System Diseases"}], "browseLeaves": [{"id": "M7115", "name": "Diabetes Mellitus", "asFound": "Diabetes Mellitus", "relevance": "HIGH"}, {"id": "M7119", "name": "Diabetes Mellitus, Type 2", "asFound": "Type 2 Diabetes", "relevance": "HIGH"}, {"id": "M11639", "name": "Metabolic Diseases", "relevance": "LOW"}, {"id": "M25403", "name": "Glucose Metabolism Disorders", "relevance": "LOW"}, {"id": "M7862", "name": "Endocrine System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC18", "name": "Nutritional and Metabolic Diseases"}, {"abbrev": "BC19", "name": "Gland and Hormone Related Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000008687", "term": "Metformin"}, {"id": "D000020909", "term": "Acarbose"}, {"id": "C000102817", "term": "Voglibose"}], "ancestors": [{"id": "D000007004", "term": "Hypoglycemic Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000065089", "term": "Glycoside Hydrolase Inhibitors"}, {"id": "D000004791", "term": "Enzyme Inhibitors"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}], "browseLeaves": [{"id": "M11667", "name": "Metformin", "asFound": "Assessment", "relevance": "HIGH"}, {"id": "M248791", "name": "Voglibose", "asFound": "Medical education", "relevance": "HIGH"}, {"id": "M22644", "name": "Acarbose", "asFound": "Thyroidectomy", "relevance": "HIGH"}, {"id": "M10054", "name": "Hypoglycemic Agents", "relevance": "LOW"}, {"id": "M5557", "name": "Cardiac Glycosides", "relevance": "LOW"}, {"id": "M30447", "name": "Glycoside Hydrolase Inhibitors", "relevance": "LOW"}, {"id": "M7951", "name": "Enzyme Inhibitors", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Hypo", "name": "Hypoglycemic Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "AnArAg", "name": "Anti-Arrhythmia Agents"}, {"abbrev": "CaAg", "name": "Cardiotonic Agents"}]}}, "hasResults": true}